Literature DB >> 33391325

Stable Protein Sialylation in Physcomitrella.

Lennard L Bohlender1, Juliana Parsons1, Sebastian N W Hoernstein1, Christine Rempfer1,2, Natalia Ruiz-Molina1, Timo Lorenz1, Fernando Rodríguez Jahnke1,2, Rudolf Figl3, Benjamin Fode4, Friedrich Altmann3, Ralf Reski1,2,5,6, Eva L Decker1.   

Abstract

Recombinantly produced proteins are indispensable tools for medical applications. Since the majority of them are glycoproteins, their N-glycosylation profiles are major determinants for their activity, structural properties and safety. For therapeutical applications, a glycosylation pattern adapted to product and treatment requirements is advantageous. Physcomitrium patens (Physcomitrella, moss) is able to perform highly homogeneous complex-type N-glycosylation. Additionally, it has been glyco-engineered to eliminate plant-specific sugar residues by knock-out of the β1,2-xylosyltransferase and α1,3-fucosyltransferase genes (Δxt/ft). Furthermore, Physcomitrella meets wide-ranging biopharmaceutical requirements such as GMP compliance, product safety, scalability and outstanding possibilities for precise genome engineering. However, all plants, in contrast to mammals, lack the capability to perform N-glycan sialylation. Since sialic acids are a common terminal modification on human N-glycans, the property to perform N-glycan sialylation is highly desired within the plant-based biopharmaceutical sector. In this study, we present the successful achievement of protein N-glycan sialylation in stably transformed Physcomitrella. The sialylation ability was achieved in a Δxt/ft moss line by stable expression of seven mammalian coding sequences combined with targeted organelle-specific localization of the encoded enzymes responsible for the generation of β1,4-galactosylated acceptor N-glycans as well as the synthesis, activation, transport and transfer of sialic acid. Production of free (Neu5Ac) and activated (CMP-Neu5Ac) sialic acid was proven. The glycosidic anchor for the attachment of terminal sialic acid was generated by the introduction of a chimeric human β1,4-galactosyltransferase gene under the simultaneous knock-out of the gene encoding the endogenous β1,3-galactosyltransferase. Functional complex-type N-glycan sialylation was confirmed via mass spectrometric analysis of a stably co-expressed recombinant human protein.
Copyright © 2020 Bohlender, Parsons, Hoernstein, Rempfer, Ruiz-Molina, Lorenz, Rodríguez Jahnke, Figl, Fode, Altmann, Reski and Decker.

Entities:  

Keywords:  N-glycan humanization; N-glycan sialylation; PMP; glyco-engineering; glyco-optimization; plant-made pharmaceuticals; plant-made recombinant biopharmaceuticals

Year:  2020        PMID: 33391325      PMCID: PMC7775405          DOI: 10.3389/fpls.2020.610032

Source DB:  PubMed          Journal:  Front Plant Sci        ISSN: 1664-462X            Impact factor:   5.753


  3 in total

1.  SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients.

Authors:  Mohau S Makatsa; Marius B Tincho; Jerome M Wendoh; Sherazaan D Ismail; Rofhiwa Nesamari; Francisco Pera; Scott de Beer; Anura David; Sarika Jugwanth; Maemu P Gededzha; Nakampe Mampeule; Ian Sanne; Wendy Stevens; Lesley Scott; Jonathan Blackburn; Elizabeth S Mayne; Roanne S Keeton; Wendy A Burgers
Journal:  Front Plant Sci       Date:  2021-03-31       Impact factor: 5.753

2.  Process Engineering of Biopharmaceutical Production in Moss Bioreactors via Model-Based Description and Evaluation of Phytohormone Impact.

Authors:  Natalia Ruiz-Molina; Juliana Parsons; Sina Schroeder; Clemens Posten; Ralf Reski; Eva L Decker
Journal:  Front Bioeng Biotechnol       Date:  2022-02-17

3.  Unexpected Arabinosylation after Humanization of Plant Protein N-Glycosylation.

Authors:  Lennard L Bohlender; Juliana Parsons; Sebastian N W Hoernstein; Nina Bangert; Fernando Rodríguez-Jahnke; Ralf Reski; Eva L Decker
Journal:  Front Bioeng Biotechnol       Date:  2022-02-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.